At the annual meeting of the European Society for Pediatric Infectious Diseases (ESPID), Sanofi (Euronext: SAN) is presenting results from a pooled analysis of data for nirsevimab.
The investigational long-acting antibody is designed to protect all infants from birth entering their first RSV season with a single dose.
One of a number of new options being developed by drugmakers looking to address a significant area of unmet medical need, the antibody could tap into a major market opportunity globally.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze